Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

NCT03241173 is registered in ClinicalTrials.gov with Incyte Biosciences International Sàrl as lead sponsor.

NCT NCT03241173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03241173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Lead sponsor
Incyte Biosciences International Sàrl
Phase
Phase 1/2
Overall status
Completed
Start date
October 9, 2017
Completion date
September 17, 2019
Enrollment
52 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies